<DOC>
	<DOCNO>NCT00298415</DOCNO>
	<brief_summary>The last ASCO recommendation 2003 treatment CBNPC stage IIIB/IV elderly people , manage monochemotherapy . Paclitaxel association carboplatin feasible elderly patient retrospective analysis two study compare SWOG , one association cisplatine vinorelbine cisplatine cisplatine vinorelbine , show among 117 70 year old patient , absence significant difference survival toxicity compare young patient . The study recently publish Lilenbaum Al show among patient bad PS , association carboplatine paclitaxel well paclitaxel . The paclitaxel manage weekly form likely well activity expose cancerous cell repeat way shorter interval without allow emergence resistant clone allow increase intensity amount . This mode administration appear time effective tolerate well among patient 70 year . The weekly association carboplatin paclitaxel test phase II show rate response 14 % one survival 1 year 31 % randomize test ( dedicate old person ) phase II 3 arm lead Belani et al.. The best combination carboplatine + paclitaxel weekly prove associate paclitaxel 100mg/m² 3 week 4 carboplatine AUC 6 J1 J1 = J29 . A test phase II dedicate 70 year old patient carry France take association carboplatine ( AUC 6 ) every 4 week paclitaxel weekly ( 90 mg/m² J1 , J8 J15 ) . This test include 51 patient highlight median 10,42 month survival ( IC 95 % : 7,29-17,05 )</brief_summary>
	<brief_title>Chemotherapy Elderly Patients With Non-Small-Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>It thus seem u justified compare standard arm , vinorelbine gemcitabine ( choice center ) monotherapy experimental arm , association carboplatine + paclitaxel . To avoid skew result introduction second line choice investigator , choose force . It thus erlotinib recent test present NCIC ASCO 2004 prove effectiveness second third line time term response especially survival compare purely palliative care .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Pathologically / cytologically proven NSCLC stage IIIB IV age &gt; = 70 year old &lt; 90 year old</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>2-years survival</keyword>
</DOC>